5-Azacytidine Potentiates Anti-Tumor Immunity in a Model of Pancreatic Ductal Adenocarcinoma

Frontiers in Immunology - Switzerland
doi 10.3389/fimmu.2020.00538
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Tumor-Stroma Interactions in Pancreatic Ductal Adenocarcinoma

Molecular Cancer Therapeutics
Cancer ResearchOncology
2007English

Tumoral EHF Predicts the Efficacy of Anti-Pd1 Therapy in Pancreatic Ductal Adenocarcinoma

Journal of Experimental Medicine
MedicineAllergyImmunology
2019English

Lung Adenocarcinoma-Intrinsic GBE1 Signaling Inhibits Anti-Tumor Immunity

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2019English

Non-Coding RNAs in Pancreatic Ductal Adenocarcinoma

Frontiers in Oncology
Cancer ResearchOncology
2020English

Pancreatic Ductal Adenocarcinoma With Cystic Features

HPB
HepatologyGastroenterology
2016English

Loss of ARID1A Expression Correlates With Tumor Differentiation and Tumor Progression Stage in Pancreatic Ductal Adenocarcinoma

Technology in Cancer Research and Treatment
MedicineCancer ResearchOncology
2018English

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)

International Journal of Medical Sciences
Medicine
2020English

Clinical Significance of MUC13 in Pancreatic Ductal Adenocarcinoma

HPB
HepatologyGastroenterology
2018English

Upregulation of miR-194 Contributes to Tumor Growth and Progression in Pancreatic Ductal Adenocarcinoma

Oncology Reports
MedicineCancer ResearchOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy